氯吡格雷药物基因组学研究进展

被引：13

作者：

祝锦

刘丽宏

机构：

[1] 首都医科大学附属北京朝阳医院

来源：

中国新药杂志 | 2013年 / 15期

关键词：

冠心病; 氯吡格雷; 药物基因组学; CYP2C19; 基因多态性;

D O I：

暂无

中图分类号：

R966 [分子药理学];

学科分类号：

100602 ; 100706 ;

摘要：

氯吡格雷是一种普遍使用的P2Y12血小板抑制剂,它和阿司匹林联合使用是预防和治疗急性冠脉综合征(ACS)以及经皮介入治疗患者的临床标准用药。氯吡格雷是药物前体,需要经过小肠的吸收和肝脏细胞色素P450(CYP)的两步代谢才能转化为有活性的代谢产物(R-130964)。研究表明氯吡格雷活性代谢物的转化主要受细胞色素P4502C19(CYP2C19)基因多态性的影响。CYP2C19失去功能型等位基因(主要是CYP2C19*2,CYP2C19*3)携带者与血浆氯吡格雷活性代谢物浓度以及生物利用度降低、不良心血管事件危险性增加有关。而ABCB1,CYP2B6等其他基因的多态性与氯吡格雷活性代谢物以及不良心血管事件的关系有待于在不同人群中进一步研究。基因检测以及通过选择适当的个性化治疗方案可以帮助携带CYP2C19*2,*3等位基因的患者减少危险,增加氯吡格雷的有效性和安全性。

引用

页码：1774 / 1778

页数：5

共 20 条

[1]

Clopidogrel and proton pump inhibitors-where do we stand in 2012?[J]. Michael D Drepper,Laurent Spahr,Jean Louis Frossard.World Journal of Gastroenterology. 2012(18)

[2] CYP2C9和CYP2C19基因多态性对健康中国人口服氯吡格雷后药效动力学的影响 [J].

蒋娟娟 ;

田蕾 ;

韩璐璐 ;

严岩 ;

黄一玲 ;

刘红 ;

谢爽 ;

李一石 .

中国新药杂志, 2011, (13) :1217-1221

[3] 我国心血管病及其主要危险因素的流行病学研究 [J].

王薇 ;

赵冬 .

首都医科大学学报, 2005, (02) :143-146

[4] Meta-Analysis of Cytochrome P450 2C19 Polymorphism and Risk of Adverse Clinical Outcomes Among Coronary Artery Disease Patients of Different Ethnic Groups Treated With Clopidogrel [J].

Jang, Jae-Sik ;

Cho, Kyoung-Im ;

Jin, Han-Young ;

Seo, Jeong-Sook ;

Yang, Tae-Hyun ;

Kim, Dae-Kyeong ;

Kim, Dong-Soo ;

Seol, Sang-Hoon ;

Kim, Doo-Il ;

Kim, Bo-Hyun ;

Park, Yong Hyun ;

Je, Hyung-Gon ;

Jeong, Young-Hoon ;

Lee, Seung-Whan .

AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (04) :502-508

[5]

CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects[J] . Mark Y Chan,Karen Tan,Huay-Cheem Tan,Pei-Tee Huan,Bei Li,Qian-Hui Phua,Hong-Kai Lee,Chi-Hang Lee,Adrian Low,Richard C Becker,Wen-Chong Ong,Mark A Richards,Agus Salim,E-Shyong Tai,Evelyn Koay.Pharmacogenomics . 2012 (5)

[6] An insight into the Interaction between Clopidogrel and Proton Pump Inhibitors [J].

Shah, Bhavik S. ;

Parmar, Sanjay A. ;

Mahajan, Shailaja ;

Mehta, Anita A. .

CURRENT DRUG METABOLISM, 2012, 13 (02) :225-235

[7]

First Analysis of the Relation Between CYP2C19 Genotype and Pharmacodynamics in Patients Treated With Ticagrelor Versus Clopidogrel: The ONSET/OFFSET and RESPOND Genotype Studies[J] . Udaya S. Tantry,Kevin P. Bliden,Cheryl Wei,Robert F. Storey,Martin Armstrong,Kathleen Butler,Paul A. Gurbel.Circulation: Cardiovascular Genetics . 2010 (6)

[8]

Efficacy of High-Dose Clopidogrel Treatment (600 mg) Less Than Two Hours Before Percutaneous Coronary Intervention in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes[J] . Dmitriy N. Feldman,Foluso Fakorede,Robert M. Minutello,Geoffrey Bergman,Issam Moussa,S. Chiu Wong.The American Journal of Cardiology . 2010 (3)

[9] The Impact of Body Mass Index on the One Year Outcomes of Patients Treated by Percutaneous Coronary Intervention With Biolimus- and Sirolimus-Eluting Stents (from the LEADERS Trial) [J].

Sarno, Giovanna ;

Garg, Scot ;

Onuma, Yoshinobu ;

Buszman, Pawel ;

Linke, Axel ;

Ischinger, Thomas ;

Klauss, Volker ;

Eberli, Franz ;

Corti, Roberto ;

Wijns, William ;

Morice, Marie-Claude ;

di Mario, Carlo ;

van Geuns, Robert Jan ;

Eerdmans, Pedro ;

Garcia-Garcia, Hector M. ;

van Es, Gerrit-Anne ;

Goedhart, Dick ;

de Vries, Ton ;

Jueni, Peter ;

Meier, Bernhard ;

Windecker, Stephan ;

Serruys, Patrick .

AMERICAN JOURNAL OF CARDIOLOGY, 2010, 105 (04) :475-479

[10] Impact of Chronic Kidney Disease on Platelet Function Profiles in Diabetes Mellitus Patients With Coronary Artery Disease Taking Dual Antiplatelet Therapy [J].

Angiolillo, Dominick J. ;

Bernardo, Esther ;

Capodanno, Davide ;

Vivas, David ;

Sabate, Manel ;

Ferreiro, Jose Luis ;

Ueno, Masafumi ;

Jimenez-Quevedo, Pilar ;

Alfonso, Fernando ;

Bass, Theodore A. ;

Macaya, Carlos ;

Fernandez-Ortiz, Antonio .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (11) :1139-1146

← 1 2 →